Date: 2015-06-25
Type of information: Nomination
Compound:
Company: Aegerion Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 25, 2015, Aegerion Pharmaceuticals announced the appointment of Gregory D. Perry as chief financial officer, effective July 6, 2015. Mr. Perry replaces David Aubuchon, interim chief financial officer, who will continue in his role as chief accounting officer of Aegerion. Gregory Perry most recently served as chief financial officer of Eleven Biotherapeutics. Prior to joining Eleven Biotherapeutics, Mr. Perry served as the interim chief financial officer of InVivo Therapeutics. Prior to joining InVivo, he served as the executive vice president and chief financial officer of ImmunoGen. Before that, he was the chief financial officer of Elixir Pharmaceuticals. Mr. Perry also previously was senior vice president and chief financial officer of Transkaryotic Therapies. Mr. Perry serves on the board of directors of Ocata Therapeutics. He received a B.A. in Economics and Political Science from Amherst College.
Financial terms:
Latest news:
